These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34626666)

  • 41. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Wauters F; Cornelissen T; Imberechts D; Martin S; Koentjoro B; Sue C; Vangheluwe P; Vandenberghe W
    Autophagy; 2020 Feb; 16(2):203-222. PubMed ID: 30945962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists.
    Alcalay RN; Kehoe C; Shorr E; Battista R; Hall A; Simuni T; Marder K; Wills AM; Naito A; Beck JC; Schwarzschild MA; Nance M
    Genet Med; 2020 Mar; 22(3):574-580. PubMed ID: 31680121
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor.
    Clark LN; Kisselev S; Park N; Ross B; Verbitsky M; Rios E; Alcalay RN; Lee JH; Louis ED
    Parkinsonism Relat Disord; 2010 Feb; 16(2):132-5. PubMed ID: 19527940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
    Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Ortega RA; Bressman SB; Raymond D; Ozelius LJ; Katsnelson V; Leaver K; Swan MC; Shanker V; Miravite J; Wang C; Bennett SAL; Saunders-Pullman R
    Mov Disord; 2022 Nov; 37(11):2217-2225. PubMed ID: 36054306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Exploratory Study Using Electronic Medical Records to Assess the Feasibility of Establishing Cohorts of Patients with Genetic Causes of Parkinson's Disease.
    Lee SJ; Shaw PM; Thornton B; Kumar A; Eizik M; Goldstaub D; Braun T; Teper G; Pai JK; Chodick G; Bienfait K; Levitan D; Beller D; Chris Min K; Jonathan D; Voss T; Fox CS; Aubrey Stoch S; Struyk AF; Vainstein G
    J Parkinsons Dis; 2022; 12(5):1645-1653. PubMed ID: 35466950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GBA1-and LRRK2-directed Treatments: The Way Forward.
    Maayan Eshed G; Alcalay RN
    Parkinsonism Relat Disord; 2024 May; 122():106039. PubMed ID: 38438297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.
    Gan-Or Z; Bar-Shira A; Mirelman A; Gurevich T; Kedmi M; Giladi N; Orr-Urtreger A
    Neurogenetics; 2010 Feb; 11(1):121-5. PubMed ID: 19458969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
    Lee CY; Menozzi E; Chau KY; Schapira AHV
    J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation.
    Angeli A; Mencacci NE; Duran R; Aviles-Olmos I; Kefalopoulou Z; Candelario J; Rusbridge S; Foley J; Pradhan P; Jahanshahi M; Zrinzo L; Hariz M; Wood NW; Hardy J; Limousin P; Foltynie T
    Mov Disord; 2013 Sep; 28(10):1370-5. PubMed ID: 23818421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of LRRK2 and GBA mutations in a Brazilian family with Parkinson's disease.
    Spitz M; Pereira JS; Nicareta DH; Abreu Gde M; Bastos EF; Seixas TL; Pimentel MM
    Parkinsonism Relat Disord; 2015 Jul; 21(7):825-6. PubMed ID: 25952961
    [No Abstract]   [Full Text] [Related]  

  • 53. Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study.
    Tropea TF; Amari N; Han N; Rick J; Suh E; Akhtar RS; Dahodwala N; Deik A; Gonzalez-Alegre P; Hurtig H; Siderowf A; Spindler M; Stern M; Thenganatt MA; Weintraub D; Willis AW; Van Deerlin V; Chen-Plotkin A
    J Parkinsons Dis; 2021; 11(2):757-765. PubMed ID: 33492247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
    Lee BD; Dawson VL; Dawson TM
    Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2.
    Dächsel JC; Mata IF; Ross OA; Taylor JP; Lincoln SJ; Hinkle KM; Huerta C; Ribacoba R; Blazquez M; Alvarez V; Farrer MJ
    Neurosci Lett; 2006 Dec; 410(2):80-4. PubMed ID: 17095157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.
    Over L; Brüggemann N; Lohmann K
    J Neuromuscul Dis; 2021; 8(3):341-356. PubMed ID: 33459660
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and molecular genetic findings of hereditary Parkinson's patients from Turkey.
    Emekli I; Tepgeç F; Samancı B; Toksoy G; Hasanoğulları Kına G; Tüfekçioğlu Z; Başaran S; Bilgiç B; Gürvit IH; Emre M; Uyguner ZO; Hanagasi HA
    Parkinsonism Relat Disord; 2021 Dec; 93():35-39. PubMed ID: 34781237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
    Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
    Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene.
    Thaler A; Bregman N; Gurevich T; Shiner T; Dror Y; Zmira O; Gan-Or Z; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
    Parkinsonism Relat Disord; 2018 Oct; 55():45-49. PubMed ID: 29784561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.
    Iwaki H; Blauwendraat C; Leonard HL; Kim JJ; Liu G; Maple-Grødem J; Corvol JC; Pihlstrøm L; van Nimwegen M; Hutten SJ; Nguyen KH; Rick J; Eberly S; Faghri F; Auinger P; Scott KM; Wijeyekoon R; Van Deerlin VM; Hernandez DG; Gibbs JR; ; Chitrala KN; Day-Williams AG; Brice A; Alves G; Noyce AJ; Tysnes OB; Evans JR; Breen DP; Estrada K; Wegel CE; Danjou F; Simon DK; Andreassen O; Ravina B; Toft M; Heutink P; Bloem BR; Weintraub D; Barker RA; Williams-Gray CH; van de Warrenburg BP; Van Hilten JJ; Scherzer CR; Singleton AB; Nalls MA
    Mov Disord; 2019 Dec; 34(12):1839-1850. PubMed ID: 31505070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.